# Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

> **NCT06121557** · PHASE1 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 24 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **PROCEDURE:** Surgery for harvesting tumor-draining lymph nodes
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Tumor-draining lymph node-derived lymphocyte (LNL)
- **BIOLOGICAL:** Interleukin-2
- **BIOLOGICAL:** Camrelizumab
- **DRUG:** Chemotherapeutic drug, ADC or PARP inhibitor

## Key facts

- **NCT ID:** NCT06121557
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121557, "Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06121557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*